Grifols 2023 Annual Report on Form 20-F filed with the SEC

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

Grifols, S.A. has filed its 2023 Annual Report on Form 20-F with the SEC, offering insights into its governance practices and financial performance. The company, a prominent player in the healthcare sector specializing in plasma-derived medicines, aims to provide transparency to investors through this filing.

Financial Analyst

The submission of Grifols' Form 20-F annual report is a standard regulatory requirement, providing a comprehensive breakdown of the company’s financial health, governance practices and operational performance. Investors should examine the revenue trends, particularly in the context of the plasma-derived medicines market. Attention should also be given to the net profit margin, an indicator of efficiency. It's worth noting whether Grifols' margins are improving, stagnant, or declining. This reflects on their operational efficacy and can influence stock valuation.

Medical Research Analyst

From a medical research perspective, Grifols' investment in R&D is a telling metric. It represents the company's commitment to innovation and future growth. Growth in R&D expenses, if present, could indicate a robust pipeline of products, which could drive future revenue. Additionally, the performance of existing products in the market, especially compared to competitors, is crucial. If Grifols is gaining or maintaining market share, it could signal the efficacy of their treatments and the strength of their commercial operations.

Market Research Analyst

Grifols operates in a highly specialized segment, where regulatory compliance and market dynamics are key. The report's details on geographic revenue distribution are important as they show how Grifols is diversifying its risk and capitalizing on global market opportunities. It’s also essential to evaluate their market positioning amidst potential regulation changes, like price caps on drugs or shifts in healthcare policies, which could significantly impact their business model and, consequently, investor returns.

BARCELONA, Spain, April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").

Grifols' annual report on Form 20-F provides investors with an overview of the company's governance practices, including information about the Board of Directors and its committees, executive compensation, and risk management. This information is critical for stakeholders to make informed decisions about investing in the company, engaging with the company on sustainability and governance issues, and assessing the company's long-term value creation potential.

Grifols' Annual Report on Form 20-F includes, among other disclosures, the financial statements of Grifols for its fiscal year ended December 31, 2023 in accordance with International Financial Reporting Standards (IFRS) as adopted by the International Accounting Standards Board that were audited and certified in compliance with internal control over financial reporting by the auditing firm KPMG Auditores, S.L. for the years 2021, 2022 and 2023.

In addition to the financial statements, the annual report includes management's discussion and analysis (MD&A) of the financial condition and results of operations, as well as information about the company's key performance indicators and sustainability initiatives. The MD&A provides insights into the company's performance over the past year, highlighting key drivers of growth and areas of concern.

Grifols' share capital is represented by 426,129,798 ordinary shares (Class A), with a nominal value of EUR 0.25 per share, and 261,425,110 non-voting shares (Class B), with a nominal value of EUR 0.05 per share. Grifols' ordinary shares (Class A) are listed on the Spanish stock market and form part of the IBEX-35 (GRF). Non-voting shares (Class B) are also listed on the Spanish stock market (GRF.P) and on NASDAQ (GRFS) through ADRs (American Depositary Receipts).

The annual report on Form 20-F can be accessed electronically through Grifols' website at http://www.grifols.com/en/investors and the SEC's website at http://www.sec.gov.

Grifols will deliver, within a reasonable time after request, a hard copy of the annual report on Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request. To request a hard copy, shareholders may contact Grifols by email at investors@grifols.com to the attention of Grifols' Investor Relations & Sustainability, Re: 2023 Annual Report on Form 20-F.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2023, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information about Grifols, please visit www.grifols.com.

For more information, please visit www.grifols.com

View original content:https://www.prnewswire.com/news-releases/grifols-2023-annual-report-on-form-20-f-filed-with-the-sec-302122482.html

SOURCE Grifols

FAQ

When did Grifols file its 2023 Annual Report on Form 20-F with the SEC?

Grifols filed its 2023 Annual Report on Form 20-F with the SEC on April 19, 2024.

What is Grifols known for in the healthcare industry?

Grifols is a global healthcare company and a leading manufacturer of plasma-derived medicines.

Which stock exchanges is Grifols listed on?

Grifols is listed on MCE under ticker symbols GRF and GRF.P, as well as on NASDAQ under the ticker symbol GRFS.

What information does Grifols' Annual Report on Form 20-F provide?

Grifols' Annual Report on Form 20-F offers investors an overview of the company's governance practices and financial performance for the fiscal year ended December 31, 2023.